Decision Memo for Screening for Cervical Cancer with Human Papillomavirus (HPV) Testing (CAG-00442N)

Decision Memo for Screening for Cervical Cancer with Human Papillomavirus (HPV) Testing (CAG-00442N)

National Coverage Analyses

Screening for Cervical Cancer with Human Papillomavirus (HPV) Testing
    Posted final decision memo
http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=278

The Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to add Human Papillomavirus (HPV) testing once every five years as an additional preventive service benefit under the Medicare program for asymptomatic beneficiaries aged 30 to 65 years in conjunction with the Pap smear test. CMS will cover screening for cervical cancer with the appropriate U.S. Food and Drug Administration (FDA) approved/cleared laboratory tests, used consistent with FDA approved labeling and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations.